FASTJEKT 300 Mikrogramm clinical trials

CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)

This study is looking into a new medicine called barzolvolimab for adults with a condition called Eosinophilic Oesophagitis. We want to see if it helps reduce inflammation in the food pipe and if it's safe to use, compared to a dummy medicine.